White paper: Are dual ARVs the new frontier in a maturing HIV market?

Raquel Núñez

Tackling and managing HIV has been one of the pharmaceutical industry’s more distinguished achievements, despite the turbulence and antagonism that marked the early days of AIDS-related R&D and the industry’s relationships with governments, patients and activists.

Therapy Watch Associate Director Raquel Nuñez, discusses continuing improvements in HIV therapies and the evolution of single-tablet regimens (STRs) over time.

HIV whitepaper
HIV whitepaper

Tackling and managing HIV has been one of the pharmaceutical industry’s more distinguished achievements, despite the turbulence and antagonism that marked the early days of AIDS-related R&D and the industry’s relationships with governments, patients and activists.

Therapy Watch Associate Director Raquel Nuñez, discusses continuing improvements in HIV therapies and the evolution of single-tablet regimens (STRs) over time.

Download the white paper

Sign up to receive Rapport

Rapport is our e-newsletter and online resource for sharing our expertise and experience in global healthcare market research.

Sign up here